The recent huge gains seen by holders of Aquinox Pharmaceuticals , Celsus Therapeutics , and Recro Pharma illustrate the potential of the Of the 35 names on the screen, I highlight Roka Biosciences, Nexvet Biopharma, OXiGENE, MEI Pharma, Biota Pharmaceuticals, Celladon, and Venaxis as names I like. I highlight Affymax, Tikro Technologies, Cadus Corporation, and Natural Alternatives International as potential investment opportunities, but cases where I need to do more due diligence.